Common use
Sofosbuvir is a revolutionary direct-acting antiviral (DAA) medication used for the treatment of chronic hepatitis C virus (HCV) infection. As a Sovaldi generic, sofosbuvir works as a nucleotide analog NS5B polymerase inhibitor — it blocks the enzyme that hepatitis C uses to replicate itself, effectively stopping the virus from multiplying in the body. When you buy Sofosbuvir online, you gain access to one of the most significant breakthroughs in hepatitis C treatment, offering cure rates exceeding 90% for many HCV genotypes.

Sofosbuvir is used for the treatment of chronic hepatitis C across all major genotypes (1, 2, 3, and 4) in combination with other antiviral medications. Depending on the HCV genotype, it may be combined with pegylated interferon and ribavirin, with ribavirin alone, or with the NS5A inhibitor ledipasvir in a highly effective interferon-free regimen. This nucleotide analog has also demonstrated excellent results in patients with HCV and HIV co-infection, expanding treatment options for this challenging patient population. The landmark ELECTRON clinical trial demonstrated that a dual interferon-free regimen of sofosbuvir plus ribavirin achieved a 100% sustained virological response (SVR24) rate in previously untreated patients with HCV genotypes 2 or 3 — meaning complete viral clearance 24 weeks after treatment completion. Sofosbuvir has transformed HCV treatment from a year-long, side-effect-heavy interferon-based ordeal into a shorter, more tolerable regimen with dramatically higher cure rates, offering genuine hope for liver health restoration to millions of patients worldwide.

Dosage and direction
The standard adult dose for chronic hepatitis C treatment is 400 mg taken orally once daily with or without food. Sofosbuvir must always be used in combination with other HCV medications — never as monotherapy. The recommended regimens and treatment durations vary by HCV genotype:

- Genotype 1 or 4 chronic hepatitis C (CHC): Sofosbuvir combined with peginterferon alfa and ribavirin for 12 weeks
- Genotype 2 CHC: Sofosbuvir combined with ribavirin for 12 weeks
- Genotype 3 CHC: Sofosbuvir combined with ribavirin for 24 weeks
- Hepatocellular carcinoma awaiting liver transplantation: Sofosbuvir combined with ribavirin for up to 48 weeks or until liver transplantation (whichever occurs first)

Treatment efficacy has been established in patients with HCV genotypes 1 through 4, including patients with hepatocellular carcinoma meeting Milan criteria awaiting liver transplant, and patients with HCV/HIV-1 co-infection. For genotype 1 CHC patients who cannot tolerate an interferon-based regimen, a 24-week course of sofosbuvir and ribavirin may be considered — this decision should be guided by a careful benefit/risk assessment for each individual patient. Sofosbuvir and ribavirin therapy is specifically recommended for patients awaiting liver transplantation to prevent post-transplant HCV reinfection and protect liver health. It is not yet established whether sofosbuvir is safe and effective in children under 18 years of age.

Precautions
It is strongly recommended to consult your doctor or pharmacist before starting this direct-acting antiviral, especially to confirm you are not allergic to sofosbuvir or any of its components, and to review all other medications you are taking for hepatitis C or any other condition. To ensure sofosbuvir is safe for you, tell your doctor if you have: liver problems other than hepatitis C (or if you have had a liver transplant), kidney disease (or if you are on dialysis), HIV infection, or if you have recently used the heart rhythm medication amiodarone (Cordarone, Pacerone), as a potentially life-threatening interaction can occur.

When sofosbuvir is used in combination with ribavirin, strict pregnancy precautions are essential because ribavirin can cause severe birth defects or fetal death. Women must have a confirmed negative pregnancy test before starting treatment and every month during the course of therapy. If pregnancy occurs while either the mother or the father is using sofosbuvir with ribavirin, inform your doctor immediately. Men should not use this drug combination if their sexual partner is pregnant. Breastfeeding is not recommended during treatment.

Taking sofosbuvir will not prevent transmission of hepatitis C to others. Continue to practice safe hygiene — do not share razors, toothbrushes, or needles, and discuss safe methods to prevent HCV transmission during sexual contact with your healthcare provider. Monitoring viral load and liver health through regular blood tests during and after treatment is essential for confirming treatment success.

Contraindications
Drinking alcohol while taking sofosbuvir can cause dangerous or unwanted side effects and may compromise liver health during treatment. Grapefruit and grapefruit juice may interact with this nucleotide analog and lead to unwanted side effects — avoid grapefruit products throughout the course of your HCV treatment. Sofosbuvir is contraindicated in patients with known hypersensitivity to the drug. When used with ribavirin, all contraindications for ribavirin also apply (including pregnancy in female patients and female partners of male patients).

Possible side effect
Contact your doctor immediately if you experience: pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating, fever, swollen or bleeding gums, painful mouth sores, skin sores, cold or flu-like symptoms, or persistent cough. These may indicate serious hematological complications when sofosbuvir is combined with ribavirin.

Common side effects of sofosbuvir-based regimens include headache, fatigue, mild itching, nausea, and sleep disturbances such as insomnia. These effects are generally mild and manageable. This is not a complete list of side effects — others may occur depending on your combination regimen. Report any unusual symptoms to your doctor for proper management of your chronic hepatitis treatment.

Drug interaction
When taking sofosbuvir, it is especially important that your healthcare provider knows if you are also taking any of the following medications, as they may reduce sofosbuvir's effectiveness or cause dangerous interactions: Amiodarone (risk of severe, life-threatening slow heart rate), Carbamazepine, Eliglustat, Fosphenytoin, Oxcarbazepine, Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, Rifapentine (all powerful enzyme inducers that can dramatically reduce sofosbuvir blood levels), St. John's Wort, Tipranavir, and Ulipristal. Provide your doctor with a complete medication list including all prescription drugs, over-the-counter products, and herbal supplements to ensure safe and effective hepatitis C treatment.

Missed dose
Take the missed dose of sofosbuvir as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose. Do not take extra medicine to make up for a missed dose, and never take more than 400 mg of sofosbuvir in one day. Consistent daily dosing is critical for achieving sustained viral clearance and protecting your liver health.

Overdose
If you suspect you have taken too much sofosbuvir, seek emergency medical attention immediately. While sofosbuvir has a relatively wide safety margin, an overdose combined with other HCV medications may increase the risk and severity of side effects. Medical professionals can provide appropriate monitoring and supportive care.

Storage
Store sofosbuvir at 25°C (77°F), with temporary excursions permitted between 15°C and 30°C (59°F and 86°F). Keep away from moisture, heat, and direct light. Store in the original container and keep all medications out of the reach of children and pets. Do not use past the expiration date.

Disclaimer
We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.